AIM: To study the adjuvant effect of mesoporous silica particles and their capability of modifying an already existing allergic Th2-like immune response. MATERIALS & METHODS: The adjuvant effect of Santa Barbara Amorphous-15 (SBA-15) mesoporous silica particles was studied in an antigen-specific ovalbumin (OVA) system in vitro and in vivo. The capacity of the OVA-loaded SBA-15 particles (SBA-15-OVA) to modify an existing immune response was assessed in a murine allergy model. RESULTS: SBA-15-OVA induced significantly stronger OVA-specific splenocyte proliferation compared with OVA alone. Significantly higher IFN-γ production was observed in ex vivo OVA-stimulated splenocytes from SBA-15-OVA-immunized mice compared with mice injected with only SBA-15 or OVA. Treatment of OVA-sensitized mice with SBA-15-OVA modified the immune response with significantly lower serum levels of OVA-specific IgE and higher IgG levels compared with the alum-OVA-treated group. CONCLUSION: The results are promising for the continued development of mesoporous silica materials for therapeutic applications.
AIM: To study the adjuvant effect of mesoporous silica particles and their capability of modifying an already existing allergic Th2-like immune response. MATERIALS & METHODS: The adjuvant effect of Santa Barbara Amorphous-15 (SBA-15) mesoporous silica particles was studied in an antigen-specific ovalbumin (OVA) system in vitro and in vivo. The capacity of the OVA-loaded SBA-15 particles (SBA-15-OVA) to modify an existing immune response was assessed in a murineallergy model. RESULTS:SBA-15-OVA induced significantly stronger OVA-specific splenocyte proliferation compared with OVA alone. Significantly higher IFN-γ production was observed in ex vivo OVA-stimulated splenocytes from SBA-15-OVA-immunized mice compared with mice injected with only SBA-15 or OVA. Treatment of OVA-sensitized mice with SBA-15-OVA modified the immune response with significantly lower serum levels of OVA-specific IgE and higher IgG levels compared with the alum-OVA-treated group. CONCLUSION: The results are promising for the continued development of mesoporous silica materials for therapeutic applications.
Authors: Martin K Rasmussen; Nikolay Kardjilov; Cristiano L P Oliveira; Benjamin Watts; Julie Villanova; Viviane Fongaro Botosso; Osvaldo A Sant'Anna; Marcia C A Fantini; Heloisa N Bordallo Journal: Sci Rep Date: 2019-04-15 Impact factor: 4.379
Authors: Atin Adhikari; Aniruddha Mitra; Abbas Rashidi; Imaobong Ekpo; Jacob Schwartz; Jefferson Doehling Journal: Int J Environ Res Public Health Date: 2018-09-07 Impact factor: 3.390
Authors: Michael Lau; Benjamin Sealy; Valery Combes; Marco Morsch; Alfonso E Garcia-Bennett Journal: Pharmaceutics Date: 2022-02-24 Impact factor: 6.525